Bharat Bio stares at losses, 5cr Covaxin doses to expire in 2023
The Times of India Hyderabad|November 07, 2022
Firm Sitting On 20Cr Doses In Bulk Form
Swati.Bharadwaj timesgroup.com
Bharat Bio stares at losses, 5cr Covaxin doses to expire in 2023

Hyderabad: Bharat Biotech is staring at the prospect of having to dump nearly 250 million doses of its Covid-19 vaccine Covaxin.

While 50 million doses lying unused in ready-to-use vials are set to expire in early 2023, the company is sitting on another 200 million doses in bulk form, a Bharat Biotech spokesperson told TOI.

The company attributed the pile-up of stocks to the lack of demand, something that it had predicted on April 1 when it announced a Covaxin production slowdown after it had wrapped up its supply obligations.

Bharat Biotech said it was staring at losses if these unused stocks were discarded on expiration but declined to quantify the losses.

Esta historia es de la edición November 07, 2022 de The Times of India Hyderabad.

Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.

Esta historia es de la edición November 07, 2022 de The Times of India Hyderabad.

Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.